ETC
NRIX icon

Exchange Traded Concepts’s Nurix Therapeutics NRIX Stock Holding History

Exchange Traded Concepts’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,145
Closed -$109K – 1477
2025
Q1 		$109K Buy
9,145
+2,562
+39% +$42.9K ﹤0.01% 1129
2024
Q4 		$124K Hold
6,583
– – ﹤0.01% 1106
2024
Q3 		$148K Sell
6,583
-8,897
-57% -$202K ﹤0.01% 1073
2024
Q2 		$323K Sell
15,480
-4,815
-24% -$75K 0.01% 813
2024
Q1 		$298K Buy
20,295
+4,472
+28% +$48.1K 0.01% 798
2023
Q4 		$163K Buy
15,823
+4,012
+34% +$27.5K ﹤0.01% 817
2023
Q3 		$92.8K Sell
11,811
-528
-4% -$4.82K ﹤0.01% 925
2023
Q2 		$123K Buy
+12,339
New +$126K ﹤0.01% 904

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Exchange Traded Concepts's NRIX Position: Q2 2025 in Review

Exchange Traded Concepts sold out of Nurix Therapeutics (NRIX) in Q2 2025, closing a stake of 9,145 shares — an estimated $109K sold.

Exchange Traded Concepts first reported a position in NRIX in Q2 2023 and held it in 8 quarters. The position peaked at $323K in Q2 2024. 163 funds tracked by Wall St. Rank hold NRIX as of Q2 2025.

  • Exchange Traded Concepts reported no remaining Nurix Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Exchange Traded Concepts sold 9,145 Nurix Therapeutics shares in Q2 2025, an estimated $109K.
  • Exchange Traded Concepts first reported a position in Nurix Therapeutics in Q2 2023 and held it in 8 quarters.
  • Exchange Traded Concepts's Nurix Therapeutics position peaked at $323K in Q2 2024.
  • 163 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2025.

Based on Exchange Traded Concepts's 13F filing for Q2 2025, filed 10 Jul 2025.